This resource hub hosts resources supported by the pharmaceutical industry and related information on NICE Implementation Collaborative projects that examine variation in best practice.

The report has been developed by Oxford Academic Health Science Network (AHSN), Innovation Agency North West Coast AHSN, and MGP and initiated on behalf of NIC, which is a collaborative including the membership, among others, of NICE, NHS England, AHSNs, and the Association of the British Pharmaceutical Industry. Innovation Agency North West Coast AHSN and Oxford AHSN have provided strategic project leadership, and Lundbeck Ltd has contributed funding support for this project. Lundbeck Ltd has had no editorial input into the content of the report but was able to review it for technical accuracy.

Despite the high negative impact of alcohol on health and wider society, alcohol dependence is still poorly recognised and managed within the NHS, and primary care in particular. Although there a number of therapies available for maintaining abstinence, nalmefene is the first pharmacological drug licensed for the reduction of alcohol consumption in people with alcohol dependence.

The NIC report on implementation of NICE Technology Appraisal (TA) 325 was based on primary and secondary research, involving clinicians and clinical commissioning group medicines management leads, conducted in selected localities across England. This work identified and explored three key barriers to implementation of NICE TA325 and the issues contributing to these barriers:

  • commissioning
  • adapting and developing services
  • delivery and patient access.

Reducing variation in care: NIC projects